TY-302 + abiraterone

TY-302 + abiraterone is an investigational oral combination therapy being evaluated primarily for metastatic castration-resistant prostate cancer (mCRPC) that has failed novel endocrine therapies. **TY-302** is a selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), a class of agents targeting cell cycle progression pathways in cancer. **Abiraterone (administered as abiraterone acetate)** is a well-established androgen biosynthesis inhibitor that works through irreversible inhibition of CYP17A1, a critical enzyme in androgen production; this blocks androgen receptor signaling that drives prostate cancer progression. The combination aims to leverage dual inhibition—cell cycle arrest via CDK4/6 inhibition (TY-302) together with androgen deprivation (abiraterone)—for greater anticancer effect. The combination is under clinical investigation in Phase Ib/II studies for mCRPC, and both drugs are administered orally in this combination. The developers are Zhengzhou Taiji Hongnuo Pharmaceutical (for TY-302) and TYK Medicines (clinical sponsor), while abiraterone products are commonly developed and manufactured by Johnson & Johnson and several generic companies.[1][2][3][5][7]

Brand names

Abiraptor

Other names

abiraterone acetate